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Anemia is common in cancer patients during chemotherapy. The study discussed in this article was primarily designed to assess
the eﬀects of epoetin alfa on transfusion requirements, hematopoietic response, quality of life (QOL), and safety in cancer patients
receiving nonplatinum–based chemotherapy under randomized, double-blind, placebo-controlled conditions. Over the course of the
study, a growing body of evidence from other studies suggested an association between low hemoglobin (Hb) levels and poorer
prognosis in patients receiving radiotherapy, chemotherapy or combination therapies. Therefore, prior to unblinding, the study
protocol was amended to explore a possible relationship between increased Hb levels and survival by collecting survival data for 12
months after the last patient completed the study. A total of 375 patients with solid tumors or nonmyeloid hematologic malig-
nancies (Hb 410.5 g/dl or Hb >10.5 g/dl but 412.0 g/dl with a decrease of 51.5 g/dl per cycle or month since starting chemo-
therapy) were randomized 2:1 to receive 150–300 IU/kg epoetin alfa (n=251) or placebo (n=124) subcutaneously three times
weekly for 12–24 weeks, or for 3–6 chemotherapy cycles plus 4 weeks after chemotherapy. The primary eﬃcacy endpoint was the
proportion of patients transfused. Secondary endpoints included changes in Hb level and QOL measurements. Hematopoietic
response in terms of the proportion of responders (patients whose Hb level increased by at least 2 g/dl during the study without
transfusion) and correctors (patients who achieved an Hb level of at least 12 g/dl during the study without transfusion) were also
determined. Compared with placebo, epoetin alfa signiﬁcantly decreased transfusion requirements (P=0.0057) and increased Hb
levels (P <0.001). There were signiﬁcantly more responders and correctors in the epoetin alfa group than in the placebo group (P
<0.001 for both). Epoetin alfa also provided signiﬁcantly greater improvements (P <0.01) in all primary cancer- and anemia-
speciﬁc QOL domains, including energy level, ability to do daily activities, fatigue and overall QOL score. Adverse events were
comparable between treatment groups. Median survival times were 17 months for epoetin alfa–treated patients and 11 months for
placebo-treated patients. Kaplan-Meier 12-month survival estimates were 60% for epoetin alfa-treated patients and 49% for placebo-
treated patients. The log-rank test indicated a trend in overall survival for epoetin alfa (P=0.13). These survival results must be
interpreted with caution because the study was not powered to assess survival, nor was it controlled for stage of disease, bone
marrow involvement, intensity of chemotherapy or disease progression. This study allowed regulatory approval of epoetin alfa for
treatment of non-cisplatin–induced chemotherapy-related anemia. Epoetin alfa also decreases the impact of anemia on QOL, and
may improve survival of cancer patients.
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Low hemoglobin (Hb) levels are common in cancer
patients and have been linked to poorer prognosis inpatients at diagnosis and in those receiving radiotherapy
or chemotherapy [1–4]. Prior research suggests that
increased Hb levels are associated with improved treat-
ment outcomes [1,2]. This may be partially explained by
studies showing that tumor hypoxia contributes to the
malignancy of cancer and that delivery of oxygen to the
tumor is important in the response to cancer treatment
[5–8]. In addition, a preclinical study of the diﬀerential
toxicity of antineoplastic therapies toward oxygenated1359-6349/$ - see front matter # 2003 Elsevier Ltd. All rights reserved.
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and hypoxic tumor sub-populations in vivo conducted in
murine ﬁbrosarcoma indicated that cells located distally
from the tumor vasculature were signiﬁcantly less aﬀec-
ted by most anticancer agents [9]. Retrospective com-
parisons indicate that correcting anemia may improve
the response to concomitant chemotherapy or radio-
therapy and may inﬂuence patient survival after radio-
therapy [2,10].
In addition to its eﬀects on clinical outcomes, anemia
has a signiﬁcant and meaningful impact on quality of
life (QOL). Eﬀective management of anemia has resulted
in marked improvements in energy level, ability to do
daily activities, and overall QOL scores in several studies
[11–16]. These eﬀects on QOL were seen when the ﬁnal
Hb levels were increased from 1.8 to 2.0 g/dl over base-
line levels of 9.2–9.5 g/dl [12–16]. These studies support
the idea that Hb levels should be increased to at least 11
g/dl for eﬀective management of anemia. Detailed ana-
lyses conﬁrmed that the greatest increase in QOL scores
is seen as the Hb increases to 11–12 g/dl [17].
The eﬀects of improving anemia on the patient’s QOL
may be independent of disease response, tumor type and
clinical outcomes [14]. Thus, QOL changes should be
considered independently as elements of the functional
status of cancer patients.
The initial purpose of the study discussed in this
paper, conducted by Littlewood et al. [16] was to assess
the eﬀects of recombinant human erythropoietin
(rHuEPO, epoetin alfa) on transfusion requirements, Hb
level, QOL and safety in patients receiving nonplatinum–
based chemotherapy under randomized, double-blind,
placebo-controlled conditions [16]. Over the course of
the study, the aforementioned growing body of evidence
from other studies suggested an association between low
Hb levels and poorer prognosis in patients receiving
radiotherapy, chemotherapy and combination radio-
chemotherapy. Therefore, prior to unblinding, the study
protocol was amended to explore a possible relationship
between increased Hb levels and survival [16]. This
study has provided justiﬁcation for QOL assessments
during cancer therapy as well as laid the foundation for
subsequent studies that have examined the clinical
signiﬁcance of improvements in QOL with reference to
elevated Hb levels.2. Patients and methods
A detailed description of study methods has been
presented elsewhere [16]. Brieﬂy, this study was a multi-
national, multicenter, double-blind, placebo-controlled,
randomized trial including 375 patients aged 18 years or
older. Inclusion criteria were: receiving or scheduled to
receive nonplatinum–based chemotherapy for solid tumor
or non myeloid hematologic malignancy; Hb 410.5
g/dl or >10.5 g/dl but 412.0 g/dl after a 51.5 g/dldecrease per month or cycle since starting chemo-
therapy; and a life expectancy of 56 months. All
patients gave written informed consent prior to entering
the study. The study protocol and amendments were
reviewed by an independent ethics committee.
The treatment schedule is summarized in Fig. 1.
Patients were randomized 2:1 to receive 150 IU/kg
epoetin alfa or a matching volume of placebo sub-
cutaneously three times weekly for a maximum of 28
weeks of study treatment, which included 12–24 weeks
(3–6 cycles) of chemotherapy and a 4-week period after
chemotherapy. (Outside of the United States, epoetin
alfa is manufactured by Ortho Biologics, LLC, and dis-
tributed and marketed as EPREX1 or ERYPO1 by
Ortho Biotech and Janssen-Cilag. In the United States,
PROCRIT1 [epoetin alfa] is manufactured by Amgen
Inc. and distributed and marketed by Ortho Biotech
Products, L.P.)
The primary eﬃcacy endpoint was the proportion of
patients transfused after the ﬁrst 4 weeks of treatment.
Secondary endpoints included change in Hb level from
baseline to last assessment and change in QOL para-
meters from baseline to last assessment. Quality of life
was assessed by the Cancer Linear Analog Scale (CLAS,
also known as the Linear Analog Scale Assessment, or
LASA) for assessment of energy levels, ability to do
daily activities, and overall QOL, and the Anemia and
Fatigue subscales of the Functional Assessment of
Cancer Therapy-Anemia (FACT-An) scale.
The proportion of responders (patients whose Hb
level increased by at least 2 g/dl during the study with-
out transfusion 30 days prior) and correctors (patients
who achieved an Hb level of at least 12 g/dl during the
study without transfusion 30 days prior) were also
determined. Transfusion-related Hb values on study
were excluded from the determination of responders
and correctors. The proportion of responders and
correctors was calculated for patients who were on
study for at least 28 days.
Data for the prospective analysis of survival, includ-
ing date and cause of death, were collected 12 months
following study end, i.e. 12 months after the last patient
ended the study period. Survival distributions were
estimated with Kaplan–Meier curves, which were
compared by means of log-rank tests. To compensate
for the variable survival times associated with diﬀerent
malignancies, Kaplan–Meier estimates of survival by
tumor strata (solid versus hematologic) were also
performed. Further analysis with the Cox regression
model was performed using a stepwise selection proce-
dure to correct for eﬀects of potential prognostic factors
on patient survival [18]. Four signiﬁcant factors—tumor
stratum, baseline Hb level, age and area under the curve
(AUC) for neutrophils—were included in the model.
For all statistical analyses, P <0.05 was considered
signiﬁcant. Subgroups had no P values computed.M. Aapro et al. / EJC Supplements Vol 2 No. 2 (2004) 20–28 21
3. Results
The demographics of the patient population are sum-
marized in Table 1; epoetin alfa and placebo groups
were demographically similar at baseline. The tumor
types associated with the treatment groups are described
in Table 2.
As shown in Fig. 2, epoetin alfa signiﬁcantly
decreased transfusion requirements (P=0.0057). Thisdecrease in the proportion transfused was observed in
patients with both solid and hematologic tumors. Since
the epoetin alfa and placebo groups had comparable
proportions of malignancies (Table 2), we can conclude
that the diﬀerences in transfusion requirements illu-
strated in Fig. 2 were not likely to be due to tumor types
but were due to treatment diﬀerences. These results
suggest that over the treatment range of 150–300 IU/kg,
epoetin alfa decreases the need for anemia-induced
blood transfusions.
In addition to the eﬀect of epoetin alfa on the trans-
fusion requirements, epoetin alfa also increased mean
Hb levels (P <0.001), as shown in Fig. 3. The time
course of this eﬀect (Fig. 3) indicates that Hb levels
increased for the ﬁrst 10–14 weeks on epoetin alfaFig. 1. Treatment schema. Patients received 150 IU/kg epoetin alfa unless Hb had increased <1 g/dl or reticulocytes had increased <40 000/ml at
week 4. The duration of chemotherapy was 3–6 cycles. Patient survival was assessed 12 months after the completion of the last patient enrolled in the
study.Table 1
Intent-to-treat patient baseline demographics of the treatment groupsDescription Epoetin alfa
(n=251)Placebo
(n=124)GenderMale 85 (34%) 39 (31%)Female 166 (66%) 85 (69%)Age (year)a 58.314.2 59.513.9
Time since diagnosis (days)a 35.347.4 31.140.3
Hb (g/dl)a 9.91.1 9.71.1
Prestudy transfusions 71 (28%) 44 (36%)Received chemotherapy
within 3 months of study231 (92%) 114 (92%)Adapted and reprinted with permission [16].
a Mean S.D.Table 2
Tumor types of treatment groupsMalignancy Epoetin alfa
(n=251)Placebo
(n=124)Solid tumor 136 (54%) 66 (53%)Breast 78 (31%) 36 (29%)Other 58 (23%) 30 (24%)Hematologic tumor 115 (46%) 58 (47%)Non-Hodgkin’s lymphoma 41 (16%) 21 (17%)Multiple myeloma 37 (15%) 25 (20%)Other 37 (15%) 12 (10%)Adapted and reprinted with permission [16].22 M. Aapro et al. / EJC Supplements Vol 2 No. 2 (2004) 20–28
therapy, while the Hb levels in the placebo group did
not signiﬁcantly diﬀer from baseline over the same
period. After 28 weeks, the mean Hb level of the epoetin
alfa group had increased by 2.22.18 g/dl (P <0.001),
while the placebo group had increased only 0.51.79
g/dl (Fig. 3). The hematopoietic eﬀect of epoetin alfa is
likely an important factor contributing to the decreased
transfusion requirements of this treatment group. Fur-
thermore, the epoetin alfa–induced increases in Hb were
of the magnitude where QOL improvements would be
anticipated [12–15].
Overall, there were signiﬁcantly more responders in
the epoetin alfa group (70.5%) than in the placebo
group (19.1%) (P <0.001) (Table 3). This eﬀect was
maintained when an evaluation of the proportion of
responders by tumor type (solid or hematologic) and
Hb stratum (410.5 g/dl or >10.5 g/dl) was performed(Table 4). Among responders, the mean study day on
which an Hb level at least 2 g/dl above baseline was
reached was earlier for the epoetin alfa group (52 days)
than the placebo group (75 days). In addition, the max-
imum mean Hb level reached among responders was
higher in the epoetin alfa group (14.2 g/dl) than in the
placebo group (12.2 g/dl).
Overall, there were signiﬁcantly more correctors in the
epoetin alfa group (67.6%) than in the placebo group
(15.7%) (P<0.001) (Table 5). This eﬀect was main-
tained upon evaluation of correctors by tumor stratum
(solid or hematologic) and Hb stratum (410.5 g/dl or
>10.5 g/dl) (Table 6). Within the epoetin alfa group,
the proportion of correctors was slightly higher in
patients with hematologic malignancies than in patients
with solid tumors, as well as in patients in the higher Hb
stratum. Among correctors, the mean study day on
which an Hb level of at least 12 g/dl was reached was
earlier for the epoetin alfa group (52 days) than the
placebo group (80 days).
As a means of evaluating the eﬀect of epoetin alfa on
the QOL of the patients, cancer- and anemia-speciﬁc
QOL domains, including energy level, ability to do daily
activities, fatigue, anemia and overall QOL scores were
determined. As shown in Figs. 4 and 5, epoetin alfa
signiﬁcantly increased the patients’ energy, ability to do
daily activities, fatigue, and anemia scores, as well as the
overall QOL scores (CLAS and FACT-An). These
results indicate that corresponding with an increase inFig. 2. Epoetin alfa decreases the proportion of patients transfused
after day 28. The proportion of patients receiving a transfusion to
correct for chemotherapy-induced anemia, the primary study end-
point, was determined for the intent-to-treat (ITT) population.Fig. 3. Epoetin alfa improves haemoglobin levels. The mean Hb levels
of the epoetin alfa (—) and placebo (- - -) populations are plotted as a
function of time after the start of the study. Error bars indicate 2
standard errors. The 28-week values for the eﬃcacy (EFF) population
and placebo groups diﬀer with P <0.001. Reprinted with permission
[16].Table 3
Proportion of respondersa (eﬃcacy population)Response Epoetin alfa
(n=244)Placebo
(n=115)P valuebResponder 172 (70.5%) 22 (19.1%) <0.001Non-responder 72 (29.5%) 93 (80.9%)a Patients whose hemoglobin increased by 52 g/dl unrelated to
transfusions.
b Fisher exact test.Table 4
Proportion of respondersa by sub group (eﬃcacy population)Sub group Epoetin alfa
(n=244)Placebo
(n=115)Tumor typeSolid 87/131 (66.4%) 13/61 (21.3%)Hematologic 85/113 (75.2%) 9/54 (16.7%)Hemoglobin
stratum410.5 g/dl 139/203 (68.5%) 22/100 (22.0%)
>10.5 g/dl 33/41 (80.5%) 0/15 (0.0%)a Patients whose hemoglobin increased by 52 g/dl unrelated to
transfusions.M. Aapro et al. / EJC Supplements Vol 2 No. 2 (2004) 20–28 23
Hb levels and a decreased need for transfusion, epoetin
alfa improved the QOL of these cancer patients.
Epoetin alfa was well tolerated. Adverse eﬀect inci-
dences have been separately reported [16] and were
comparable between treatment groups (results not
shown).
The survival results must be interpreted with caution
because the study was not powered suﬃciently to
deﬁnitively assess survival, nor was it controlled forstage of disease, bone marrow involvement, intensity of
chemotherapy, or disease progression. Nevertheless, the
Kaplan–Meier 12-month survival estimates were 60%
for epoetin alfa–treated patients and 49% for placebo-
treated patients (Figs. 6 and 7). Median survival times
were 17 months for epoetin alfa–treated patients and 11
months for placebo-treated patients. The log-rank test
indicated a trend in overall survival for epoetin alfa
(P=0.13).
Using the stepwise selection procedure of the Cox
regression model, eight inclusion covariates were exam-
ined. Tumor type, age, baseline Hb level and neutrophil
AUC were found to be signiﬁcant. Including theseTable 5
Proportion of correctorsa (eﬃcacy population)Response Epoetin alfa
(n=244)Placebo
(n=115)P valuebCorrector 165 (67.6%) 18 (15.7%) <0.001Non corrector 79 (32.4%) 97 (84.3%)a Patients who achieved hemoglobin 512 g/dl unrelated to
transfusions.
b Fisher exact test.Table 6
Proportion of correctorsa by sub group (eﬃcacy population)Sub group Epoetin alfa
(n=244)Placebo
(n=115)Tumor typeSolid 83/131 (63.4%) 10/61 (16.4%)Hematologic 82/113 (72.6%) 8/54 (14.8%)Hemoglobin stratum410.5 g/dl 127/203 (62.6%) 14/100 (14.0%)
>10.5 g/dl 38/41 (92.7%) 4/15 (26.7%)a Patients who achieved hemoglobin 512 g/dl unrelated to trans-
fusions.Fig. 4. Improved CLAS QOL scores by epoetin alfa versus placebo.
The QOL CLAS scores from the beginning of the study to the last
assessment were compared for epoetin alfa and placebo groups. The
change in the patient’s perceived energy level, ability to do daily
activities, and overall QOL scores are shown for the epoetin alfa and
placebo groups. Reprinted with permission [16].Fig. 5. Improved FACT-An QOL scores by epoetin alfa versus
placebo. The QOL FACT-An scores from the beginning of the
study to the last assessment were compared for epoetin alfa and
placebo groups. The change in the patient’s perceived fatigue, anemia,
and overall (FACT-G) QOL scores are shown for the epoetin alfa and
placebo groups. Reprinted with permission [16].Fig. 6. Kaplan-Meier estimates of patient survival of epoetin alfa
versus placebo. Kaplan–Meier probabilities were estimated for the
epoetin alfa (—) and placebo (- - -) treatment groups over the course
of the study. Adapted and reprinted with permission [16].24 M. Aapro et al. / EJC Supplements Vol 2 No. 2 (2004) 20–28
covariates in the model, the estimated hazard ratio
(placebo versus epoetin alfa) was 1.309 (P=0.052),
indicating that the risk of dying during the follow-up
period was 31% higher for the patients receiving placebo.4. Discussion
Many placebo-controlled and open-label clinical
studies have demonstrated the safety and eﬃcacy of
epoetin alfa for the treatment of anemia in patients
undergoing chemotherapy [13–16,19–23]. The results of
these studies consistently indicated that epoetin alfa
signiﬁcantly increased Hb levels and decreased the need
for blood transfusions. In the large-scale community-
based studies, the increase in Hb levels was associated
with improvements in the patient’s energy level, their
ability to do daily activities, and their overall QOL [13–
15]. The results of Gabrilove et al. [15] utilized a once-
weekly dosing regimen of epoetin alfa. In one study [14],
there was a correlation between changes in Hb levels
and changes in overall QOL that was independent of the
response to chemotherapy.
The present study examined the administration of
epoetin alfa to anemic cancer patients receiving non-
platinum–based chemotherapy and its eﬀect on the
proportion of patients requiring transfusion, change in
Hb levels and change in QOL scores. The placebo-con-
trolled results conﬁrm the eﬀects seen in earlier studies.
The proportion of patients requiring transfusions after
the ﬁrst 4 weeks of treatment was signiﬁcantly smaller in
the epoetin alfa group than in the placebo group(P=0.0057) and the epoetin alfa–treated group had a
signiﬁcantly greater increase in Hb levels than did the
placebo group (P <0.001). Similar increases in Hb
levels were seen for epoetin alfa–treated patients in the
tumor and Hb strata. This increase in Hb levels for the
epoetin alfa–treated patient also resulted in improve-
ments in QOL that were not seen in placebo patients.
Thus, these ﬁndings, which were obtained under
randomized, placebo-controlled conditions, conﬁrm
and strengthen the validity of the previously described
work [13–15,19–22].
In addition to the eﬀect of epoetin alfa on transfusion
requirements and Hb levels, the results of the present
study demonstrated a signiﬁcant and beneﬁcial eﬀect of
epoetin alfa on QOL measures. The results showed sig-
niﬁcant (P 40.0048) increases for epoetin alfa over
placebo for ﬁve cancer- and anemia-speciﬁc primary
QOL measures (FACT-G Total, FACT-An Fatigue
subscale, CLAS: energy level, CLAS: ability to do daily
activities, CLAS: overall QOL), and one secondary
cancer- and anemia-speciﬁc QOL measure (FACT-An
anemia subscale). It is important to note that these
improvements in QOL were not seen in the placebo-
treated patients. Again, these results, which were
obtained under double-blind, placebo-controlled condi-
tions and evaluated by rigorous statistical procedures,
conﬁrmed previously published studies that evaluated
the eﬀect of epoetin alfa on QOL [13–15,19–21].
In addition to the established relationship between
Hb levels and QOL, there appears to be a possible rela-
tionship between Hb levels and patient survival. Analy-
sis of the collected survival data in the present study
revealed median survival times of 17 months with epoe-
tin alfa and 11 months with placebo. Kaplan-Meier
estimates showed a trend in survival favoring epoetin
alfa (P=0.126). When examined by tumor stratum, this
trend continued for both solid and hematologic tumor
groups and also compensated for the longer survival
associated with hematologic malignancies. Further ana-
lysis with the Cox regression model controlling for
potential prognostic factors (age, tumor stratum, base-
line Hb level and AUC for neutrophils) conﬁrmed the
trend to increased survival overall. The meaning of the
survival data is limited because the study was not con-
trolled for variables that have an inﬂuence on survival,
such as stage of disease, bone marrow involvement,
intensity of chemotherapy and disease progression,
and these data were not collected during the follow-up
period. Thus, the longer survival of the epoetin alfa
treatment group must be interpreted with caution. For
the patient with advanced cancer, such an increase in
survival time combined with a signiﬁcant improvement
in QOL would be important.
As in the present study which showed a trend in
overall survival for cancer patients who received anemia
treatment, a multivariate analysis of 191 patients whoFig. 7. Kaplan–Meier estimates of patient survival by tumor type.
Kaplan–Meier probabilities were estimated for the solid ( and )
and hematologic ( and ) tumors for the epoetin alfa ( and
) and placebo ( and ) treatment groups over the course of
the study. Tumor types are further classiﬁed in Table 2. Adapted and
reprinted with permission [16].M. Aapro et al. / EJC Supplements Vol 2 No. 2 (2004) 20–28 25
received chemoradiotherapy and surgery for head and
neck cancer found that higher Hb levels and use of
epoetin alfa were independent prognostic factors for
improved response to chemoradiotherapy and loco-
regional control (P <0.01) [2]. Conversely, recent
publications have questioned survival beneﬁts with
epoetin [24,25], although interpretation of these study
results is complicated due to diﬀerences in study design
(chemotherapy vs radiotherapy), population (non-
anemic vs anemic) and post-trial analyses. These con-
founding results support the need for further investi-
gation in this area. However, there are substantial data
demonstrating the positive prognostic eﬀect of non-
anemic hemoglobin levels.
In a retrospective study that examined the importance
of Hb levels during radiotherapy in 605 patients who
had carcinoma of the cervix, results showed that aver-
age weekly nadir Hb (AWNH) level was correlated sig-
niﬁcantly with local control, disease-free survival and
overall survival [26]. Furthermore, a review of 60 pub-
lished papers reporting survival of cancer patients
according to either Hb levels or presence of anemia
found that anemia was associated with shorter survival
times for patients with a variety of cancer types [27].
The relative increased risk of death in anemic patients
ranged from 19% for lung carcinoma to 67% for lym-
phoma. The overall estimated increase in risk was 65%.
In summary, the results of the present study show that
epoetin alfa is eﬀective in signiﬁcantly reducing the
proportion of patients transfused, increasing Hb levels,
and improving QOL in anemic cancer patients receiving
non platinum–based chemotherapy. While the study
was not designed or powered to evaluate survival, a
trend in overall survival favoring patients treated with
epoetin alfa was observed.Acknowledgements
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